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Abstract
To determine the target of the recently identified lead compound NSC130362 that is respon-
sible for its selective anti-cancer efficacy and safety in normal cells, structure-activity rela-
tionship (SAR) studies were conducted. First, NSC13062 was validated as a starting
compound for the described SAR studies in a variety of cell-based viability assays. Then, a
small library of 1,4-naphthoquinines (1,4-NQs) and quinoline-5,8-diones was tested in cell
viability assays using pancreatic cancer MIA PaCa-2 cells and normal human hepatocytes.
The obtained data allowed us to select a set of both non-toxic compounds that preferentially
induced apoptosis in cancer cells and toxic compounds that induced apoptosis in both can-
cer and normal cells. Anti-cancer activity of the selected non-toxic compounds was con-
firmed in viability assays using breast cancer HCC1187 cells. Consequently, the two sets of
compounds were tested in multiple cell-based and in vitro activity assays to identify key fac-
tors responsible for the observed activity. Inhibition of the mitochondrial electron transfer
chain (ETC) is a key distinguishing activity between the non-toxic and toxic compounds.
Finally, we developed a mathematical model that was able to distinguish these two sets of
compounds. The development of this model supports our conclusion that appropriate quan-
titative SAR (QSAR) models have the potential to be employed to develop anti-cancer com-
pounds with improved potency while maintaining non-toxicity to normal cells.
Introduction
Despite the advances achieved in the detection and treatment of early cancer that have contrib-
uted to declining cancer-specific mortality in the United States, metastatic cancer remains in
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most cases an incurable disease. In this context, identifying new drugs and designing more
efficacious and safe cancer treatments to prevent relapse in patients and to treat metastatic dis-
ease are clearly needed to provide an impact on cancer mortality rates.
One promising strategy for successful cancer therapy is to induce oxidative stress and followed
by apoptosis in cancer cells but not in normal cells. Elevated levels of reactive oxygen species
(ROS) and subsequent oxidative stress are hallmarks of carcinogenesis and metastasis providing
a potential selective cytotoxicity index [1–3]. Our data and recent studies by others demonstrated
that elevated levels of ROS can be exploited in vitro and in vivo to preferentially target cancer cells
while sparing normal cells [4–7]. The ROS-based approach to induce apoptosis in cancer cells is
conceptionally different from conventional therapy targeting well known oncogenes and tumor
suppressors—a therapy which is often ineffective due to multiple genetic and epigenetic alter-
ations in cancer cells and the ability of cancer cells to upregulate compensatory mechanisms [8,
9]. The shortcomings of conventional targeted therapy approaches have prompted the develop-
ment of alternative approaches. Instead of targeting specific oncogenes and tumor suppressors,
exploiting common biochemical alterations in cancer cells, such as an increased ROS stress,
could provide the basis for developing selective and potent therapeutic agents.
To cope with increased production of ROS, mammalian cells have developed two major
electron donor systems, the thioredoxin (Trx) system and the glutathione (GSH) system [10,
11]. The Trx redox system is composed of thioredoxin reductase (TrxR), Trx, and NADPH
while the GSH redox system is composed of GSR, GSH, and NADPH. The Trx and GSH sys-
tem represent two complementary defense systems against oxidative stress. Other redox-sensi-
tive enzymes that play a role in the oxidative stress response include Trx- and GSH-
peroxidase, GSH-S-transferase (GST), and isocitrate dehydrogenase [12–14]. Thus, targeting
any of these components can potentially induce oxidative stress which can result in cell death.
We recently reported the discovery of 1,4-naphthoquinine (1,4-NQ) derivative, NSC130362,
which inhibits GSR and, as a consequence, induces oxidative stress and subsequent apoptosis in
cancer cells but not in normal human primary hepatocytes. NSC130362 also showed anti-tumor
activity in vivo [7]. In addition to inhibiting GSR, 1,4-NQs can be reduced by NADH/NADPH
dehydrogenase followed by autoxidation, which results in the formation of ROS and potential oxi-
dative stress. The extent of autoxidation is dependent on the type and position of substituents.
1,4-NQs can also reduce cell viability via arylation of cellular nucleophiles such as GSH, DNA,
RNA and proteins and also by inhibition of DNA synthesis or mitochondrial function [15–17]. In
the current work, we tested different activities of NSC130362 and its analogs with the aim of iden-
tifying the factors responsible for enabling NSC130362’s selective anti-tumor activity. Based on
the obtained results, we were able to construct a mathematical model that could distinguish toxic
NSC130362 analogs from analogs that were non-toxic to normal cells.
Materials and methods
Reagents
All reagents were from Sigma, unless otherwise indicated. CellTiter-Glo reagent was from Pro-
mega. Glutathione reductase (GSR) activity kit was from Cayman. GSR producing plasmid
was a kind gift of Dr. Becker (Justus-Liebig University Giessen). GSR was expressed in BL21
(DE3) cells and purified by both metal chelating and affinity chromatography on 2’,5’-
ADP-Sepharose as described [18].
Cells
Human prostate carcinoma, breast, and pancreatic carcinoma cells were obtained from
ATCC. Chemotherapy resistant prostate carcinoma cells were from Dr. Korkola. Human
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primary hepatocytes were obtained from Lonza. All cells were cultured according to the provi-
der’s guidelines. Bone marrow aspirates or peripheral blood samples were collected from acute
myeloid leukemia (AML) patients under an OHSU Institutional Review Board (IRB) approved
research collection protocol which covers in vitro drug testing of leukemia cells and genetic
studies. Patients signed an IRB-approved written consent form after verbal consent was
obtained. Mononuclear cells were isolated from peripheral blood samples using a Ficoll gradi-
ent and viability of isolated mononuclear cells was assayed using Guava Viacount reagent. All
patients were treated in accordance with the ethical guidelines laid out in the Declaration of
Helsinki. AML cells were cultured in RPMI medium supplemented with 10% fetal bovine
serum.
Hydrogen peroxide cell-based assay kit
Cells were incubated for 2 h with either compounds (30 μM) or DMSO in a 96-well plate.
After the treatment, 80 μl of cell culture medium was collected and the level of hydrogen per-
oxide was determined using a Hydrogen Peroxide Cell-Based Assay kit (Cayman).
Glutathione reductase (GSR) activity assay
Recombinant GSR (0.5 u/well) in a 96-well plate was incubated in the GSR assay buffer (50
mM potassium phosphate buffer, pH 7.5 supplemented with 1 mM EDTA), 100 μl with and
without compound (30 μM) for 2 h at 25˚C. At the end of incubation, 100 μl of solution con-
taining NADPH (0.087 mM), oxidized glutathione (GSSG) (0.95 mM) and 1 μl of the reagent
that detects ratio of GSSG to reduced glutathione (GSH) (Abcam) were added and the mixture
was incubated for an additional 1 h at 25˚C. GSR activity was measured by using 490-nm exci-
tation and monitoring fluorescence at 520 nm with a fluorescence plate reader. One unit of
GSR activity was defined as the amount of enzyme required to produce 1 μM of GSH in a total
reaction volume of 200 μl in 1 minute in the GSR assay buffer containing NADPH (0.087
mM), GSSG (0.95 mM) and 1 μl of GSH/GSSG ratio detection reagent (Abcam).
NADH/NADPH dehydrogenase-mediated ROS generation assay
Recombinant NADH/NADPH dehydrogenase (0.5 units/well) in a 96-well plate was incubated
in 100 μl of the assay buffer (50 mM potassium phosphate buffer, pH 7.5 supplemented with 1
mM EDTA) containing NADPH (3 μM) and superoxide dismutase (SOD) (100 units/well)
with and without compound (30 μM) for 4 h at 37˚C. At the end of incubation, the level of
hydrogen peroxide was measured using a Hydrogen Peroxide Assay kit (Cayman). Control
samples were without NADH/NADPH dehydrogenase. The rate of NADH/NADPH dehydro-
genase- and compound-mediated ROS production was determined by subtracting values that
were obtained in the absence of NADPH dehydrogenase. One unit of NADH/NADPH dehy-
drogenase was defined as the amount of enzyme required to reduce 1.0 μmole cytochrome C
per min/mg in the presence of menadione substrate at 37˚C. One unit of SOD was defined as
the amount of enzyme required to inhibit reduction of cytochrome C by 50% in a coupled sys-
tem with xanthine oxidase at pH 7.8 at 25˚C in a 3.0 mL reaction volume. Xanthine oxidase
concentration should produce an initial ΔA550 of 0.025 ± 0.005 per min.
MitoCheck Complex I activity assay
MitoCheck Complex I activity was determined as described in the manual of the manufactur-
er’s manual (Cayman). Briefly, compounds (30 μM) or DMSO were mixed with the Complex I
activity assay buffer that contained bovine heart mitochondria reagent, NADH, and
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ubiquinone in the presence of KCN to inhibit complex IV activity. The level of Complex I
activity was monitored in a kinetic assay of NADH oxidation by measuring a decrease in
absorbance at 340 nm. The residual Complex I activity was calculated by dividing the rate of
compound wells by the rate of DMSO wells for the linear portion of the curve.
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) activity assay
Cells were incubated for 2 h with either compounds (30 μM) or DMSO in a 6-well plate. Next,
cells were collected in 200 μl of PBS and disrupted by sonication. Insoluble material was
removed by centrifugation. The level of GAPDH activity was determined by GAPDH activity
assay kit (BioVision).
Small-molecule compounds
NSC130362 and its analogs were obtained from the NCI/DTP Open Chemical Repository
(http://dtp.nci.nih.gov/repositories.html). Clinical drugs were purchased as dry powders from
Cayman.
Statistical analysis
The results of the different assays are expressed as mean values based on at least three repli-
cates. The statistical significance of differences in the treatment outcomes was determined by
one-way ANOVA or t-tests.
Results
Characterization of NSC130362 as a lead compound
The NIH has defined several requirements that should be met for a compound to be consid-
ered as a starting material for drug discovery programs [19]. Starting compounds should (1)
elicit a reproducible response in at least two assay types and have a dose-response over a hun-
dred-fold concentration range; (2) be analytically validated in terms of integrity and purity; (3)
demonstrate adequate potency; (4) possess a tractable starting point of chemical optimization
with no obvious major chemical liabilities. Most of these requirements were addressed in our
previous publication [7]. Thus, we demonstrated that our lead compound, NSC130362 (Fig
1A) selectively induces reproducible responses in either oxidative stress or caspase 3/7 activity
assays in cancer cells. We also showed that its combination with different oxidative stress
inducers, such as arsenic trioxide (ATO), myricetin (Myr), and buthionine sulfoximine (BSO),
caused cell death in a variety of breast, pancreatic, prostate, and lung carcinoma cell lines as
well as in human melanoma MDA-MB-435 and AML cells from patients. Finally, NSC130362
demonstrated anti-tumor activity in vivo [7]. To complement these results, we performed
dose-response studies in pancreatic carcinoma MIA PaCa-2 cells (Fig 1B). The obtained data
clearly showed that NSC130362 induced a dose-response over a hundred-fold concentration
range in the presence of ATO. In addition, the structure of NSC130362 was verified via proton
NMR and compound purity was at least 97% as determined by HPLC with UV detection at
280 nm. According to the structure, this compound can be easily modified to produce chemi-
cally related analogs [20].
NSC130362 is a 1,4-NQ. Quinone moieties are present in many drugs such as anthracy-
clines, daunorubicin, doxorubicin, mitomycin, and saintopin, which are used in anti-cancer
therapy [15]. The effects of quinones on cell viability are mainly due to generation of reactive
oxygen species (ROS) or to covalent attachment to biomolecules via arylation reactions [15,
21]. In addition to their ability to induce oxidative stress, ROS-generating agents can also
Targeting mitochondria in cancer therapy
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potentiate the ability of clinical drugs to induce apoptosis in cancer cells [22–24]. To test
whether NSC130362 is able to promote the cytotoxic effect of anti-cancer drugs, we performed
cell viability assays using chemotherapy resistant PANC1 and YAPC pancreatic carcinoma
cells (Fig 2). We found that NSC130362 significantly increased the ability of all tested pancre-
atic cancer drugs [25] to induce apoptosis in PANC1 and YAPC cell lines. To further validate
these findings, we analyzed a variety of chemotherapy resistant prostate carcinoma cells in cell
viability assays using prostate cancer drugs docetaxel and enzalutamide (MDV3100) either
alone or in combination with NSC130362 (Fig 3). For comparison purposes, we also included
FDA-approved ATO in this analysis. Our selection of ATO was based on our previous findings
showing that ATO and NSC130362 exhibited synergistic responses against multiple cancer
cells [7]. As we expected, NSC130362 efficiently potentiated the effect on cell viability of either
ATO or MDV3100. NSC130362 also potentiated docetaxel-induced cytotoxicity, but to a lesser
extent most likely because docetaxel was more cytotoxic as monotherapy than MDV3100 and
ATO. Finally, we performed screening of small-molecule kinase inhibitor libraries [26] with
and without NSC130362 against freshly isolated primary acute myeloid leukemia (AML) cells
obtained from patients. Encouragingly, NSC130362 decreased EC50 (cytotoxicity) of several
Fig 1. A, Structure of NSC130362. B, Dose response curve of NSC130362 in MIA PaCa-2 cells. Cells were pre-
incubated with NSC130362 for 2 h followed by addition of ATO (5 μM) and incubation for an additional 24 h. At the
end of the treatment, the ratio of dead cells was determined by a CellTiterGlo reagent. P<0.05.
https://doi.org/10.1371/journal.pone.0205623.g001
Targeting mitochondria in cancer therapy
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kinase inhibitors by 1000-fold (Supporting Information S1 Table). We also found that there
were a number of shared kinase inhibitors across leukemia cells from three different patients
whose activity was significantly induced (more than 10 times) by NSC130362. In summary, in
Fig 2. Combined treatment of NSC130362 with pancreatic cancer drugs against PANC1 and YAPC cells. Cells were pre-incubated with NSC130362 (10 μM) for 2 h
followed by addition of drugs (10 μM) and incubation for an additional 24 h. At the end of the treatment, the ratio of dead cells was determined by a CellTiterGlo
reagent. The first bar is NSC130362 alone. �, P<0.05.
https://doi.org/10.1371/journal.pone.0205623.g002
Fig 3. Combined treatment of NSC130362 with ATO, docetaxel, and MDV3100 against prostate cancer cells. Cells were pre-incubated with NSC130362 (10 μM) for
2 h followed by addition of drugs (10 μM) and incubation for an additional 24 h. At the end of the treatment, the ratio of dead cells was determined by a CellTiterGlo
reagent. The first bar in the treatment of each cell line is NSC130362 alone. �, P<0.05.
https://doi.org/10.1371/journal.pone.0205623.g003
Targeting mitochondria in cancer therapy
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these independent analyses, NSC130362 exhibited synergistic anti-tumor activity against dif-
ferent cancer cell types when combined with distinct FDA-approved drugs and kinase inhibi-
tors. Based on these findings, we conclude that NSC139362 is a promising starting compound
for further characterization.
Mechanisms underlying NSC130362-mediated effects in cancer cells
To elucidate the mechanism of synergy between NSC130362 and ATO, we analyzed the effect
of a reducing environment on cytotoxic activity mediated by the NSC130362/ATO combina-
tion. The rationale for this assay was based on the knowledge that NSC130362, in addition to its
ability to induce ROS via NADH/NADPH dehydrogenase-mediated reaction, targets GSR, an
enzyme that maintains the reducing environment of the cell and is critical in resisting oxidative
stress. In turn, ATO interferes with numerous intracellular signal transduction pathways that
may result in the induction of apoptosis, the inhibition of tumor growth, and angiogenesis [27].
These effects, at least in part, are mediated via interaction of ATO with redox-sensitive proteins
and enzymes. Almost all ATO-interacting proteins are protected against oxidation by the highly
reduced intracellular environment that is controlled by GSR. Thus, GSR inhibition could facili-
tate ATO-mediated oxidation of intracellular proteins resulting in a synergistic induction of
apoptosis in cancer cells. In agreement, our data showed that the effect of NSC130362/ATO
combination is inhibited by dithiothreitol (DTT) (Fig 4). Thus, we conclude that the effect of
NSC130362 on ATO-mediated cytotoxicity is mediated, at least in part, by its ability to induce
ROS and/or inhibit GSR. We also tested the effect of hypoxic conditions on the activity of
NSC130362/ATO combination. The effect of low level of oxygen on NSC130362/ATO-medi-
ated cytotoxicity in MIA PaCa-2 cells was less pronounced than that of DTT (Fig 4).
Structure-activity relationship studies of NSC130362 analogs
To evaluate the effect of substituents on the cytotoxic activity of NSC130362 analogs toward
cancer and normal cells, we analyzed cell viability after treatment with compounds in the
Fig 4. Effect of DTT and hypoxic conditions on the activity of NSC130362/ATO combination in MIA PaCa-2
cells. Cells were pre-incubated with NSC130362 (3 μM) in either normal (24% O2) or hypoxic (0.5% O2) conditions for
2 h in the presence or absence of DTT (3 mM) followed by addition of ATO (5 μM) and incubation for an additional
24 h. At the end of the treatment, the ratio of dead cells was determined by a CellTiterGlo reagent. P<0.05.
https://doi.org/10.1371/journal.pone.0205623.g004
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absence or presence of ATO using pancreatic cancer MIA PaCa-2 cells and human primary
hepatocytes. We selected MIA PaCa-2 cells because these cells are highly responsive to ROS
[7]. These cells were also selected because of their robust engraftment in immunodeficient
mice and sensitivity to ROS-inducing agents in vivo. Importantly, the results obtained in MIA
PaCa-2 cells are similar to those obtained in breast and other cancer cells [7]. We selected
hepatocytes as normal cells because hepatocytes are mediate toxicity to multiple drugs and are
used as a standard to assess toxicity of drugs in vitro [28]. We then determined the selective
cytotoxicity index of each NSC130362 analog by dividing the EC50 (cytotoxicity) measured in
hepatocytes by that obtained in cancer cells in the presence of ATO. Because ATO and
NSC130362 showed clear synergy against MIA PACa-2 cells (Fig 1) [7], the selective cytotoxic-
ity index was related to the combined treatment, however, data for monotherapy were also
provided. ATO at the concentration of 5 μM did not affect the viability of both MIA PACa-2
cells and human hepatocytes. For comparison with the standard of care, doxorubicin was also
included in this analysis. In addition to its effect on DNA replication, doxorubicin is also
known as an oxidative stress inducer [29].
We performed SAR studies to understand the chemical–biological interaction controlling
cytotoxicity in MIA PaCa-2 cells without affecting the viability of human hepatocytes. To
cover more chemical space, in addition to 1,4-NQs, quinoline-5,8-diones were also analyzed
(Fig 5).
First, we analyzed 2-chloro-3-amino-1,4-NQ and 2-chloro-3-(alkylamino)-1,4-NQs (Fig 6).
SAR results showed that the cytotoxic activity of compounds 1–9 in cancer cells depends on
the size of the 3-substituent. The anti-cancer potency and selective cytotoxicity index
decreased with increased length of the substituent. When compounds with branched 3-(alkyla-
mino) substituent (compounds 10–13) were analyzed, we also noticed a decrease in cytotoxic
activity and selective cytotoxicity index when the length of alkyl chain is changed from isopro-
pyl (compounds 10) to either sec-butyl or isobutyl (compounds 11 and 12, respectively). How-
ever, when the alkyl group was tert-butyl (compounds 13) there was a significant increase in
the anti-cancer activity and selective cytotoxicity index. We conclude that the shape of 4-car-
bon alkyl group plays an important role in the biological activity of the analyzed compounds.
The importance of the shape of the alkyl substituent in 2-chloro-3-(alkylamino)-1,4-NQs can
be drawn from study of compounds 14–16. In this case, when two hydrogens of the amino
group are substituted by either two methyl groups (compound 14) or aziridine groups (com-
pound 15), the resulting compounds have similar cytotoxic activity in MIA PaCa-2 cells to a
compound when one hydrogen of the amino group is substituted by the methyl group
Fig 5. Structure of 1,4-NQ and quinoline-5,8-dione.
https://doi.org/10.1371/journal.pone.0205623.g005
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(compound 2). However, the effect of these substitutions on toxicity to hepatocytes was more
pronounced. Compounds 14 and 15 were approximately 2 and 6.5 times more toxic toward
hepatocytes than compound 2, respectively. Strikingly, when two methyl groups were attached
to the aziridine group (compound 16), the compound became completely non-toxic against
normal cells, while maintaining almost identical levels of anti-cancer activity with that of com-
pound 15. These data showed again that the shape of the 3-substituent is an important factor,
which is responsible for the compound’s biological activity. Unfortunately, the steric contribu-
tion of the 3-position substituents is difficult to predict due to the absence of data regarding
target protein/compound interactions.
Next, we analyzed different 2-chloro-3-(hydroxylalkylamino)-1,4-NQs where the alkyl
group contains single hydroxyl groups (compounds 17–19). In contrast to compounds 3 and
4, change of the 2-hydroxyethyl group (compound 17) for either 3-hydroxypropyl (compound
Fig 6. EC50 values and the selective cytotoxicity index of the NSC130362 analogs that contain 3-chloro substituent in MIA PaCa-2 cells and hepatocytes.
Doxorubicin was included as a reference compound. Standard deviation for all EC50 values does not exceed 10%. To calculate the selective cytotoxicity index
for compounds that have the EC50 value above 90 μM, EC50 values were equated to 90 μM. P<0.05.
https://doi.org/10.1371/journal.pone.0205623.g006
Targeting mitochondria in cancer therapy
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18) or 2-hydroxypropyl (compound 19) had little effect on the anti-cancer activity but
increased toxicity to hepatocytes approximately 3-fold. In compounds 3 and 4, changing of the
ethyl group for the propyl group had little effect on toxicity to hepatocytes but reduced anti-
cancer activity more than 3-fold. On the other hand, exchange of the ethyl group in compound
3 for the isopropyl group (compound 10), had little effect on activity against cancer cells or
hepatocytes. We conclude again that shape of the alkyl chain in the 3-position contributes to
the biological activities of the compounds. To analyze the effect of hydroxyl substitution in the
alkyl group, we compared compounds 3 vs 17, and 4 vs 18 vs 19. While, compounds 3 and 17
had similar anti-cancer activity and toxicity towards hepatocytes, addition of a hydroxyl group
to the propyl group to generate 3-hydroxypropylamino (compound 18) and 2-hydroxypropy-
lamino (compound 19) substituent resulted in approximately 2- and 4-fold increase in anti-
cancer activity and toxicity to hepatocytes, respectively. We conclude that the hydroxyl group
non-specifically increases cytotoxic activity of compounds 18 and 19. In contrast, addition of 3
hydroxyl groups to the tert-butylamino substituent of compound 13 to generate compound
20, resulted in approximately 50- and 2-fold loss in anti-cancer activity and toxicity to hepato-
cytes, respectively. These data suggest that the effect of hydroxyl group in the 3-alkylamino
substituent is variable and depends on the length and shape of the alkyl chain.
We also analyzed the effect of different alkoxyamino substituents on biological activity of
2-chloro-3-(alkoxyamino)-1,4-NQs (compounds 21–26). As in the case with compounds 3
and 4, change of the 2-methoxyethylamino substituent (compound 21) for 3-methoxypropyla-
mino group (compound 22) resulted in a 4-fold decrease in anti-cancer activity with little
effect on toxicity to hepatocytes. However, the effect of attachment of a methoxy group to the
C-2 position of the propylamino substituent (compound 23) on anti-cancer activity is less pro-
nounced with a decrease in toxicity to hepatocytes of almost 3-fold. These data again point to
the significance of steric effects of the 3-position substituents in 2-chloro-3-(alkoxyamino)-
1,4-NQs. A similar trend in decreased anti-cancer activity with increasing the length of 3-sub-
stituent was seen when the 2-methoxyethylamino substituent in compound 21 was changed
for the 2-ethoxyethylamino (compound 24), the 3-isopropoxypropyl (compound 25) or the
3-butoxypropylamino group (compound 26). However, while compounds 21, 24, and 25 have
similar toxicity to hepatocytes (EC50 = 23–29), the presence of 3-butoxypropylamino substitu-
ent in compound 26 drastically increased toxicity to hepatocytes (EC50 = 3.6). The positive
affect of a methoxy group on the anti-cancer activity was seen by comparing compounds 3 vs
21, and 4 vs 22 but the presence of a methoxy group also increased toxicity to hepatocytes
approximately 3-fold. In contrast, attachment of a methoxy group at the C-2 position of 3-pro-
pylamino substituent (compound 23) resulted in a 6-fold improved anti-cancer activity with-
out significant effect on toxicity to hepatocytes as compared to compound 4. By comparing
compounds 21 vs 24, and 22 vs 25 vs 26, it was evident that increasing the length of alkoxy
attachment to the 3-alkylamino substituent decreased anti-cancer activity and can, as in the
case of compound 26, increase toxicity to hepatocytes. We conclude that because the alkoxy
group can have different effects on anti-cancer activity and toxicity to hepatocytes (compare
compounds 4 vs 22 and 4 vs 23), it is possible, via careful selection of the C-3 position substitu-
ent, to improve anti-cancer potency while maintaining low toxicity to hepatocytes. A 10.8-fold
improvement in the anti-cancer activity of compound 4 was seen when the 3-propylamino
substituent was extended by the dimethylamino group (compound 27), however, it also
increased toxicity to hepatocytes 9.2 times. When the 3-propylamino substituent of compound
4 was extended by the bis(2-hydroxyethyl)amino moiety (compound 28), anti-cancer activity
and toxicity to hepatocytes were increased 4.6- and 3.0-fold, respectively.
Both, the presence of carbonyl group and increasing the length of the C-3 position substitu-
ent were unfavorable in relation to the development goals as was evidenced by gradual
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decrease in the anti-cancer activity and an increase in the toxicity to hepatocytes of com-
pounds 29, 30, 31, and 32 as compared to compound 1. Substitution of hydrogen with a chloro
group in the 3-acethylamnio substituent of compound 29 to generate compound 33, caused
2-fold decrease in the anti-cancer activity. Extension of the C-3 position amino substituent in
compound 1 by either the 2-oxo-2-hydroxyethyl (compound 34) or the 2,2,2-trifluoroaceta-
mide group (compound 35) also decreased the anti-cancer activity and increased toxicity to
hepatocytes. We conclude that in all cases the presence of a carbonyl group in the C-3 position
substituent made the compound less potent in relation to cancer cells and more toxic in rela-
tion to normal cells indicating a loss of selectivity toward cancer cells. Similarly, either a
decrease in anti-cancer activity and/or loss of tumor selectivity was observed when the exten-
sion of the 3-amino substituent in compound 1 was a phenethyl (compound 36), a pyridine
(compound 37), a 1,3-thiazole (compound 38) or a phenyl group with or without fluorine,
chlorine, hydroxyl, and methyl groups at different positions (compounds 39–45). We con-
clude that various extensions of the 3-amino group of 2-chloro-3-amino-1,4-NQ is detrimental
to anti-cancer activity and selective cytotoxicity index. A lack of significant cancer cell specific-
ity and reduced anti-cancer activity were also observed regardless of whether triazadien or
3,5-dimethylmorpholin was at the C-3 position (compounds 46 and 47). The highest selective
cytotoxicity index (>90) and low EC50 (0.2 and 1.0 μM) in cancer cells were for compounds
that have a 3-amino (compound 1) and a 3-(2,3-dimethylaziridin-1-yl) (compound 16) sub-
stituent, respectively. For comparison, a potent anti-cancer drug doxorubicin showed similar
EC50 in MIA PaCa-2 cells (0.2 μM), but its selective cytotoxicity index was approximately 25
times less (Fig 6).
According to our MS/MS analysis, NSC130362 efficiently reacts with GSH and most likely
with any accessible sulfhydryl group present in a cysteine residue of proteins [7]. We believe
that this reactivity is responsible for the short half-life of NSC130362 in the bloodstream. In
the previous studies, we also showed that this reaction does not affect the ability of NSC130362
to inhibit GSR and cause oxidative stress. Based on this information, we selected the next set of
1,4-NQs that do not contain 2-chloro substituent (Fig 7).
We compared 1,4-NQs with 2-chloro-1,4-NQs that have identical C-3 position substituent
to determine the role of the 2-chloro group in compound activity. Removal of the C-2 position
chloro group in compounds 3, 4, 5, and 12 to generate compounds 48, 49, 50, 51, and 52
reduced anti-cancer activities. When the C-3 position substituent was a primary amino group
(compounds 1 and 48), this chlorine removal increased toxicity to hepatocytes approximately
3-fold. In all other pairs, removal of the C-2 chloro group did not significantly affect toxicity to
hepatocytes. We also noticed that with increasing the length of 3-alkylamino substituent, the
effect of 2-chloro group on the anti-cancer activity was decreased. For example, when com-
pounds have a 3-ethylamino substituent (compounds 3 and 49), a 2-chlorine insertion was
associated with a marked increase in cytotoxicity in MIA PaCa-2 cells, while the presence of a
3-propylamino (compounds 4 and 50), 3-isobutylamino (compounds 12 and 52), and 3- buty-
lamino (compounds 5 and 51) substituent gradually decreased the effect of the 2-position
chloro group on anti-cancer activity.
On the other hand, exchange of the C-2 position chlorine in 2-chloro-3-(dimethylamino)-
1,4-NQ (compound 14) and 2-chloro-3-(aziridin-1-yl)-1,4-NQ (compound 15) for a methoxy
group to generate compounds 53 and 54, respectively did not significantly affect the anti-can-
cer activity but greatly reduced toxicity to hepatocytes. Moreover, exchange of the C-2 position
chlorine in compound 15 for a methyl group (compound 55) increased the anti-cancer activity
2-fold and reduced toxicity to hepatocytes more than 10-fold. Again, we see the opposite effect
of the substitution on the activity toward cancer and normal cells. Based on these data, we con-
clude that the C-2 position chlorine substituent (such as in NSC130362) was not necessary for
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the anti-cancer activity and when a compound contains either the C-3 position dimethylamino
(compound 53) or aziridin-1-yl (compound 54 and 55) substituent, it resembles NSC130362
in terms of anti-cancer activity and low level of toxicity to hepatocytes.
We also analyzed 1,4-NQs with or without C-3 position amino substituents. In comparing
1,4-NQ (compound 56) with 3-amino-1,4-NQ (compound 48) and 3-alkylamino-1,4-NQs
(compounds 49–52), it was found that, in contrast to compounds 48–52, 1,4-NQ does not
exhibit any tumor selectivity. Among compounds 48–52 and 56, 3-amino-1,4-NQ (compound
48) was the most active against cancer cells and its tumor selectivity was reflected by the selec-
tive cytotoxicity index equal to 6.9. In contrast to 1,4-NQ and 3-amino-1,4-NQ (compounds
56 and 48), all tested 3-alkylamino-1,4-NQs (compounds 49–52) were completely non-toxic
to human hepatocytes (EC50 > 90 μM). We conclude that the presence of 3-alkylamino sub-
stituent confers tumor selectivity. Similarly, insertion of a 2-(2-hydroxyethylamino)ethyla-
mino, a 1-piperidinyl or a 2-diethylamino group at 3-position (compounds 57–59) increased
EC50 in cancer cells compared to that of 1,4-NQ (compound 56), and eliminated any detect-
able toxicity to hepatocytes (EC50 > 90 μM). In contrast, insertion of a C-3 position 2-hydro-
xyethylsulfanyl group (compound 60) resulted in slightly decreased EC50 in both cancer
(EC50 = 1.8 μM) and normal (EC50 = 1.7 μM) cells. Another reference compound, menadione
[30] (compound 61), which is 3-methyl-1,4-NQ, showed 1.5-fold improved anti-cancer activ-
ity as compared to 1,4-NQ (compound 56) and it was approximately 5 times less toxic to hepa-
tocytes (EC50 = 15.6 μM).
Finally, we analyzed quinoline-5,6-diones (Fig 8). When the naphthalene unit of the
1,4-NQ backbone of compound 1 (2-chloro-3-amino-1,4-NQ) was replaced with a quinoline,
the resulting compound 62 almost completely lost tumor selectivity without losing anti-cancer
activity. On the other hand, the same exchange of the 1,4-backbone in compound 14 and 48 to
generate compound 63 and 64, respectively did not significantly affect either the anti-cancer
activity or toxicity to hepatocytes, while the conversion of compound 49 into compound 66
improved the anti-cancer activity more than 30 times without affecting toxicity to hepatocytes.
These data suggest that either the type of the 3-position substituent or the presence of the
2-chloro group in a 1,4-NQ derivative influences the effect of the naphthalene/quinoline
exchange on either the anti-cancer activity or toxicity to hepatocytes. Furthermore, either
complete removal of the C-2 position substituent or exchange of the 2-chloro group with bro-
mine in compound 61 to generate compounds 64 or 65, reduced both the anti-cancer activity
and toxicity to hepatocytes. We conclude that the 7-position substituent in quinoline-
5,6-diones, which corresponds to the C-2 position substituent in 1,4-NQs, also contributes to
the level of the anti-cancer activity and toxicity to hepatocytes. Interestingly, when the 6-posi-
tion primary amino group of compound 64 was replaced by an anilino group, creating com-
pound 67, a well-known GSR inhibitor LY83583, anti-cancer activity increased approximately
10-fold, while toxicity to hepatocytes was decreased 3-fold. It is noteworthy that the effect of
the amine/aniline exchange in compound 64 to generate compound 66 is opposite to that of
the amine/aniline exchange in compound 1, where the resulting compound 39 had 8-fold
reduced anti-cancer activity and completely lost tumor selectivity. These data again suggest
that careful selection of substituents in the quinone unit of either 1,4-NQs or quinoline-
5,6-diones can result in improved anti-cancer activity and without negative effect on
hepatocytes.
Fig 7. EC50 values and the selective cytotoxicity index of the NSC130362 analogs that do not contain 2-chloro
substituent in MIA PaCa-2 cells and hepatocytes. Standard deviation for all EC50 values does not exceed 10%. To
calculate the selective cytotoxicity index for compounds that have the LC50 value above 90 μM, EC50 values were
equated to 90 μM. P<0.05.
https://doi.org/10.1371/journal.pone.0205623.g007
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Activities of the selected NSC130362 analogs
For further analyses, we used compounds that have the selective cytotoxicity index either
above 20 (non-toxic compounds) or below 1 (toxic compounds) with the aim to identify tar-
gets that are responsible for the selective activity of the identified compounds toward cancer
cells. To confirm that the effects of the selected compounds are not only specific to MIA PaCa-
2 cells, we evaluated their cytotoxic activities on breast carcinoma HCC1187 cells (Table 1).
HCC1187 cells were chosen because these cells are highly responsive to ROS [7]. For easy com-
parison, the data with MIA PaCa-2 cells were also included in Table 1. With only a few excep-
tions, all non-toxic compounds had a selective cytotoxicity index above 10 in HCC1187 cells.
We also noticed that, again with a few exceptions, HCC1187 cells are more resistant to the
non-toxic compounds in the presence of ATO as compared to MIA PaCa-2 cells. In contrast,
HCC1187 cells are more sensitive to all toxic compounds in the presence of ATO as compared
to MIA PaCa-2 cells. The high sensitivity of HCC1187 cells to toxic compounds contributed to
the increased selective cytotoxicity index. In fact, all selected compounds had a selective cyto-
toxicity index above 1 for HCC1187 cells. Based on these results we conclude that despite the
difference in sensitivity to some compounds, targeting both HCC1187 and MIA Paca-2 cells
by the non-toxic compounds most likely occurs via shared mechanisms.
The marked difference in the anti-tumor activity and selective cytotoxicity index between
the non-toxic and toxic compounds (Table 1) indicates that these two groups of compounds
should differ in either physicochemical properties or biological activities. Analysis of lipophili-
city indicates that both the non-toxic and toxic compounds have similar distribution
Fig 8. EC50 values and the selective cytotoxicity index of NSC130362 analogs in MIA PaCa-2 cells and
hepatocytes. Standard deviation for all EC50 values does not exceed 10%. P<0.05.
https://doi.org/10.1371/journal.pone.0205623.g008
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coefficient LogD that ranges from 0 to 3.45. We conclude that the analysis of the octanol-water
partitioning is not sufficient to establish a link between degree of lipophilicity and biological
activities of the selected compounds.
The cytotoxic effects of quinones have been attributed to several mechanisms: (i) DNA
damage mediated via inhibition of DNA topoisomerase-II [31]; (ii) production of ROS via
NADH/NADPH dehydrogenase-mediated formation of semiquinone radical that can reduce
oxygen to produce super oxide [15]; (iii) inhibition of glyceraldehyde 3-phosphate dehydroge-
nase (GAPDH) [16], (iv) inhibition of GSR [7, 16, 32], (v) alkylation of cellular nucleophiles
such as GSH, DNA, RNA and proteins, and (vi) inhibition of mitochondrial function [16, 21].
To elucidate the type of compound activity which is responsible for its cytotoxic effects in can-
cer cells and which is tolerated in normal cells, we performed various in vitro and cell-based
activity assays (Table 1).
ROS induction in MIA Paca-2 cells and hepatocytes. As the first step, we evaluated the
ability of the selected compounds to induce ROS in cancer and normal cells. Cells were incu-
bated with the compounds for 4 h and the level of ROS induction was measured by a hydrogen
peroxide cell-based assay kit. Compounds were assayed at a fixed concentration of 30 μM and
the measured level of hydrogen peroxide was expressed as percentage in relation to DMSO-
treated cells (100%). As shown in Table 1, all non-toxic compounds induced more ROS in can-
cer cells than in hepatocytes. This distinction was more evident for compounds with the high-
est selective cytotoxicity index. Approximately half of the toxic compounds also induced more
ROS in cancer cells than in normal cells. We conclude that the selective induction of ROS in
cancer cells is required but not sufficient factor for the selective anti-tumor activity.
NADH/NADPH dehydrogenase-mediated redox cycling. As the next step, we examined
the capability of the selected compounds to generate ROS in the presence or absence of NADH/
NADPH dehydrogenase (Table 1). ROS can be generated by NADH/NADPH-dehydrogenase via
the one electron reduction of a quinone ring of 1,4-NQs [15, 33]. Unstable half-reduced quinones
(semiquinones) transfer electrons to molecular oxygen, thus generating superoxide anion radicals
(O2
-), which are converted by SOD to hydrogen peroxide [34]. We believe that our assay measur-
ing compound’s ability to generate H2O2 in the presence or absence of NADH/NADPH dehydro-
genase more closely resembles conditions inside the cell than the assay designed to measure
compound’s redox potential values. In agreement with this hypothesis, it has been shown that
rates of NADH/NADPH dehydrogenase-mediate quinone reduction do not correlate with the
half-wave reduction potential values of quinones [33]. To determine the ability of compounds to
induce ROS, compounds were incubated for 4 h at 37˚C with and without NADH/NADPH-
dehydrogenase in the presence of NADPH as an electron donor and SOD to convert generated
superoxide radicals into hydrogen peroxide. At the end of incubation, 10-acetyl-3,7-dihydroxy-
phenoxazine (ADHP) and horseradish peroxidase (HRP) were added to the reaction and the level
of HRP-mediated formation of the fluorogenic product, resorufin, was measured on a plate
reader. ROS production was detected in reactions with either the toxic or non-toxic compounds.
Surprisingly, we noticed that some toxic compounds generate more ROS in the absence of
NADH/NADPH dehydrogenase than its presence. Based on these results, we conclude that the
ability to generate ROS via NADH/NADPH-dehydrogenase mediated redox cycling cannot be
the sole factor contributing to the selective anti-cancer activity of the tested compounds.
Effect on mitochondrial function. To further investigate the mechanism of anti-cancer
activity, we evaluated the ability of the selected compounds to target mitochondria because
inhibition of mitochondrial function by 1,4-NQs can be lethal to a cell [16]. Complex I consist-
ing of NADH dehydrogenase constitutes one of the major sites of electron entry into the mito-
chondrial electron transport chain (ETC). Complex I catalyzes the transfer of two electrons
from NADH to ubiquinone to form ubiquinol and finally to the terminal electron acceptor,
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molecular oxygen. During this process, four protons are moved from mitochondria to the
transmembrane space forming a pH gradient and an electrical potential across the inner mito-
chondrial membrane, which are required for oxidative phosphorylation. To test possible
effects of compounds on ETC, we analyzed the Complex I-mediated NADH oxidation using a
MitoCheck Complex I Activity Assay Kit. The level of NADH oxidation was measured by a
decrease in absorbance at 340 nm and expressed as percentage of residual activity in relation
to DMSO-treated mitochondria (Table 1). Addition of either non-toxic or toxic compounds to
bovine heart mitochondria at a concentration of 30 μM caused both inhibition and stimulation
of NADH oxidation. We noticed that the set of the non-toxic compounds mostly consists of
inhibitors of Complex I activity, while the set of the toxic compounds does not have any Com-
plex I inhibitory activity, except compound 39 that inhibited mitochondrial function by 9%. It
is noteworthy that because both Complex I and NADH/NADPH-dehydrogenase use NADH
as a source of electrons, observed activity of Complex I does not correspond to the actual Com-
plex I activity. Complex I activity was estimated by the rate of NADH oxidation which was also
affected by NADH/NADPH-dehydrogenase-mediated redox cycling. Indeed, we noticed that
compounds 1, 31, 32, 36, 60, and 66 that stimulated Complex I Activity by more than 30%
also induced a high level of ROS in the NADH/NADPH dehydrogenase-mediated reaction in
vitro. Thus, increased activity of Complex I most likely was observed due to the increased
NADH oxidation by NADH/NADPH-dehydrogenase. On the other hand, compounds that
both inhibited Complex I and stimulated ROS production actually were more potent inhibi-
tors than can be estimated by the level of Complex I inhibition, because they also promoted
NADH oxidation by NADH/NADPH-dehydrogenase. Altogether, these data suggest that
there was a bias of the non-toxic compounds to inhibitors of Complex I activity.
GSR Inhibition activity. Next, we evaluated the inhibitory activity of the selected com-
pounds against human GSR enzyme using recombinant GSR and Abcam GSH/GSSG ratio
detection reagent (Table 1). Briefly, GSR activity was measured by following oxidized glutathi-
one (GSSG) reduction in the presence of NADPH and expressed as percentage of residual
activity with respect to DMSO-treated enzyme. The residual activity of GSR for both the non-
toxic and toxic compounds was quite heterogeneous, ranging from 100% (compounds 38) to
3% (compound 32). Remarkably, two compounds 31 and 32 with the lowest selective cytotox-
icity index were the most potent inhibitors of GSR. We thus conclude that GSR inhibitory
activity alone cannot be used to predict the selective cytotoxicity index.
GAPDH Inhibition Activity. As a final step, we evaluated the inhibitory activity of the
selected compounds against human GAPDH enzyme in a cell-based assay using MIA PaCa-2
cells (Table 1). Cells were pre-incubated with compounds for 2 h at 37˚C followed by cell lysis
using sonication and GAPDH activity assay. The ability of compounds to inhibit GAPDH was
expressed as percentage of GAPDH residual activity with respect to DMSO-treated cells. As
shown in Table 1, most compounds inhibited GAPDH by 0 to 27%. Similar to the GSR activity
assay, only two of the most toxic compounds 31 and 32, were able to inhibit GAPDH by 95
and 97%, respectively. Based on these data, we conclude that inhibition of GAPDH is not the
activity responsible for the selective cytotoxicity of the non-toxic compounds.
To evaluate if any nontoxic compounds’ activities in the described cell-based and in vitro
assays were significantly different from those of the toxic compounds, we calculated average
activity values for each type of assay and determined the ratio between the nontoxic and toxic
compounds (Fig 9). In addition, we performed a two-tailed t-test to determine if the difference
in activities of the nontoxic and toxic compounds is significant or not. Our data showed that
despite that the calculated ratios varied from 0.63 (ROS increase in MIA PaCa-2 cells) to 1.26
(GAPDH activity assay), only the effect of the nontoxic and toxic compounds on mitochon-
drial ETC is significantly different (P = 0.029) (Fig 9).
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Quantitative SAR (QSAR) model
The mechanism of anti-tumor action of the non-toxic compounds should differ from that of
the toxic compounds. Based on the obtained results we determined that except targeting mito-
chondrial ETC, the non-toxic compounds do not exhibit biological activities that are clearly
distinct from those of toxic compounds. Since targeting mitochondria could involve different
proteins and enzymes and chemical reactions of quinones are complex, we assumed that
molecular modeling, which takes into account all available physicochemical properties of ana-
lyzed molecules, is an appropriate tool to identify key structural features that are associated
with the observed selective cytotoxic activity. To accomplish this task, we employed the
Q-MOL molecular modeling package (www.q-mol.com) [7, 35, 36] that uses a novel proprie-
tary approach to take into account molecular flexibility, a common roadblock for many other
molecular modeling tools. Taking into account the structure of the non-toxic and toxic com-
pounds, Q-MOL developed a mathematical model or fitness function to distinguish accurately
compounds with desired properties (anti-tumor activity and safety toward normal cells) (Fig
10). This fitness function was based on atom field potentials (AFPs) which, in turn, were
Fig 9. Activities of the nontoxic and toxic compounds. Ratio of activity average values between the nontoxic and
toxic compounds in cell based and in vitro assays described in Table 1. P value for difference in activities of the
nontoxic and toxic compounds in each type of assay is indicated below the corresponding bar.
https://doi.org/10.1371/journal.pone.0205623.g009
Fig 10. QSAR modeling of NSC130362 analogs. A. 3-D alignment of NSC130362 analogs. Red, blue and green color denote oxygen, nitrogen, and chlorine atoms,
respectively; B, the distribution of the non-toxic (selective cytotoxicity index above 20) and toxic (selective cytotoxicity index below 1) analogs in relation to AFP; C, an
average of AFPs for the nontoxic and toxic compounds. P<0.05.
https://doi.org/10.1371/journal.pone.0205623.g010
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derived from molecular mechanics force field. As shown in Fig 10, the resulting mathematical
model shows that the non-toxic compounds have higher (less negative) AFPs than the toxic
compounds.
Discussion
Recently, we published that NSC130362 inhibits GSR and, as a consequence, induces ROS and
subsequent apoptosis in cancer cells but not in normal human hepatocytes as a model for
hepatotoxicity [7]. Elevated ROS as compared to normal cells have been detected in almost all
cancers. ROS promote tumor development and progression. To cope with the increased ROS,
tumor cells also express increased levels of antioxidant proteins. A goal for ROS-based cancer
therapy will be the ability to either target the antioxidant proteins that are used by tumor cells
to detoxify from ROS or affect ROS producing pathways that result in increased ROS produc-
tion. By achieving this goal, the ROS-based treatment could result in selective induction of
apoptosis in cancer cells [1–7]. The aim of this study was two-fold: (1) to identify specific bio-
logical activities or structural features, which are responsible for the observed selective anti-
cancer activity and (2) to determine whether a QSAR model could be designed for the develop-
ment of potent anti-cancer compounds that are non-toxic toward normal cells. The NIH has
defined several necessary conditions that should be met for validation of a compound to be
target for optimization studies. Some of these conditions such as reproducible response in dif-
ferent assay types and adequate anti-tumor activity were addressed in our previous work [7].
To further validate NSC130362 as a candidate molecule for further characterization and/or
development, we performed additional cell-based assays. ROS inducers and GSR inhibitors are
also considered as drug sensitizers [22–24, 37]. Indeed, we showed that NSC130362 potenti-
ated anti-tumor potency of all tested pancreatic and prostate cancer drugs and decreased EC50
(cytotoxicity) of several kinase inhibitors by up to 3-logs (1000 times) in leukemia cells directly
ex vivo from patients. The ability to potentiate the cytotoxic activity of various anti-cancer
agents is a valuable property of NSC130362. This conclusion is based on the fact that under
treatment, cancer cells often adapt and develop resistance to anti-cancer drugs. To maximally
exploit chemotherapy as a therapeutic strategy, it would be meaningful to combine anti-cancer
agents with compounds that target these adaptive mechanisms. One of the mechanisms of
adaptation that can confer chemoresistance is upregulation of antioxidant pathways. In agree-
ment, there is accumulating evidence showing improved treatment outcome when anti-cancer
drugs are combined with ROS-inducing agents [22–24]. In line with this evidence, our data
also suggest that anti-cancer activity of the NSC130362/ATO combination is affected by the
reducing environment inside cancer cells. It may be the case that targeting GSR activity, which
controls the reducing environment in cancer cells, makes them susceptible to ATO and thus
inducing apoptosis by altering redox-sensitive proteins and enzymes [27]. The reason that the
effect of hypoxic conditions on the activity of the NSC130362/ATO combination is not pro-
nounced is likely because ETC can function efficiently at oxygen levels as low as 0.5% [38].
However, we also noticed that NCS130362 had negative effect on the action of some com-
pounds as seen in Fig 3A and Supporting Information S1 Table. We think that NSC130362
could have negative effect on the action of some compounds because these compounds could
exert negative effect on cancer cells by their antioxidant activities [39]. Because NSC130362
induces ROS and subsequent oxidative stress, its action could counteract the action of
antioxidants.
In addition, NSC130362 belongs to the class of 1,4-NQs that consists of important and
widely distributed compounds with a variety of pharmacological properties. 1,4-NQs contain
two ketone groups which have the ability to accept electrons and generate ROS via NADH/
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NADPH dehydrogenase-mediated redox cycling mechanism [15, 33]. 1,4-NQs can also react
with different biological targets. The NCI have identified the quinone moiety as an important
pharmacophore element for anti-cancer drugs [40] because it possesses several tumor-selective
activities such as anti-proliferative and anti-angiogenesis activity [41, 42], ability to induce oxi-
dative stress, apoptosis and necrosis [43], ability to inhibit DNA replication [44], ability to sup-
press glycolysis and mitochondrial function [15], and ability to inhibit NF-κB and STAT3
signaling [37, 45]. As a consequence, quinone moieties are present in many cancer drugs such
as anthracyclines, daunorubicin, doxorubicin, and mitomycin [15].
To determine structural features of NSC130362, which are responsible for the selective
anti-cancer activity, we performed SAR analysis of NSC130362 analogs. In the course of SAR
studies, we focused on changes to the quinone moiety of NSC130362 because 1,4-NQ deriva-
tives with various substitutions in C-2 and C-3 positions have been shown to exhibit potent
anti-cancer properties [20, 46]. Because we were interested in identifying mechanisms under-
lying the selective anti-cancer cytotoxicity, the non-toxic compounds (selective cytotoxicity
index above 20] and toxic compounds (selective cytotoxicity index below 1] were, therefore,
selected for further experiments. Our studies support the following model: (1) One of the most
important findings is that the C-2 chloro group of NSC130362 is dispensable for its activity
and it can be removed to potentially improve pharmacokinetics (PK) and safety of the com-
pound. The highly reactive C-2 chloro group may contribute to the short half-life of
NSC130362 in the mouse bloodstream [7]. In addition, in agreement with our data, chlorine
insertion at C-3 contributes to redox potential and reduced the selective cytotoxicity index,
which was determined by comparing the IC50 measured in cancer cells versus that obtained in
normal fibroblasts [47]. These results are consistent with the chloro group at the C-2 position
contributing to selectivity toward cancer cells. (2) The presence of the carbonyl group in the
C-3 substitution group in all cases reduced the selective cytotoxicity index, indicating a loss of
selectivity toward cancer cells. (3) Two most toxic analogs (MIA PaCa-2-related selective cyto-
toxicity index = 0.2) almost completely inhibited GAPDH. Previous papers described the
involvement of GAPDH in growth and programmed cell death in hepatocytes suggesting a
link between GAPDH and toxicity to hepatocytes [48, 49]. However, further analysis is needed
to determine whether the GAPDH inhibitory activity is associated with toxicity in hepatocytes.
The findings indicate a strong SAR among different 1,4-NQs and quinoline-5,8-diones and
highlight the significance of functional groups as substituents in these compounds affecting
their anti-cancer activity and selective cytotoxicity index.
1,4-NQ has limited solubility in aqueous solutions. Converting the naphthalene backbone
of 1,4-NQ into a quinoline by introduction of a nitrogen atom at C-5 or at C-8 can increase
aqueous solubility. However, introduction of a nitrogen atom at the C-5 or at C-8 of 1,4-NQ
derivative menadione can increase the oxidant character of the molecule [32, 50]. To explore
this modification, we compared compounds 1 vs 62, 14 vs 63, 48 vs 64, and 49 vs 66. While in
the case of compounds 1 vs 62, the introduction of quinoline resulted in 64-fold increase in
toxicity to hepatocytes without any noticeable effect on anti-cancer activity, the same modifi-
cation in either compound 14 or 48 did not significantly affect either anti-cancer activity or
toxicity to hepatocytes. In contrast, conversion of 1,4-NQ backbone in compound 49 to gener-
ate compound 66 resulted in more than 30-fold improved anti-cancer activity without any vis-
ible effect on toxicity to hepatocytes. We conclude that the effect of naphthalene/quionoline
exchange depends on the presence of the 2-chloro substituent and functional groups at the C-
3 and, most likely, at other positions. More detailed analysis of different substitutions in the
described or other positions of either naphthalene or quinolone backbones would require
additional compounds be synthesized to make conclusive observations which is beyond the
scope of this study.
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With the aim of identifying the biological activity of the tested compounds that is responsi-
ble for the selective cytotoxicity in cancer cells, we tested the non-toxic (selective cytotoxicity
index is above 20) and toxic (selective cytotoxicity index is below 1) compounds in a variety of
cell-based and in vitro assays. In earlier studies it has been shown that the cytotoxic activity of
1,4-NQ is directly dependent on the redox potential, which accounts for the semiquinone pro-
duction followed by autoxidation of semiquinone and generation of ROS [15, 20]. Hovewer,
redox potentials of compounds cannot accurately predict their effects inside the cells because
rates of NADH/NADPH dehydrogenase-mediate quinone reduction do not correlate with the
half-wave reduction potential values of quinones [33]. For these reasons, we tested the selected
compounds in cell-based assays as well as in direct in vitro ROS assays in the presence or
absence of recombinant NADH/NADPH dehydrogenase to analyze the compound’s ability to
generate ROS. While all non-toxic compounds preferentially induce ROS in cancer cells, five
out of nine toxic compounds also induced more ROS in cancer cells than in normal cells. In
addition, the results of NADH/NADPH dehydrogenase-based in vitro assay confirmed that
ROS-inducing capability cannot be the sole factor contributing to the value of the selective
cytotoxicity index. Moreover, we noticed that three toxic compounds generated more ROS in
the absence of NADH/NADPH dehydrogenase than when this enzyme was present in the
reaction. We conclude that at least some toxic compounds induce ROS in cancer cells and
hepatocytes by a mechanism that does not involve NADH/NADPH dehydrogenase.
To control the level of ROS and maintain redox homeostasis, mammalian cells have devel-
oped multiple strategies that inactivate ROS and prevent its accumulation. One such strategy is
governed by the GSH/GSR-based electron donor system. Thus, compounds that target GSR
can induce oxidative stress and subsequent cell death. To explore this possibility, we tested the
selected compounds in in vitro GSR activity assays. All non-toxic compounds exhibited a mod-
erate level of GSR-inhibiting activity ranging from 17% (compound 55) to 67% (compound 1),
while the toxic compounds had much wider range from 7% (compound 8) to 99% (compound
32). We also noticed that the level of induced ROS in cancer cells does not necessarily correlate
with the ability of compounds to produce ROS in vitro and inhibit GSR. This discrepancy can
be explained by the different ability of compounds to penetrate cells where the compound’s
intracellular concentration could be 100–1000 times higher than its extracellular concentration
as has been described for phenylethyl isothiocyanate (PEITC) [51, 52]. In addition, there are
additional pathways that regulate ROS production and levels in cells that do not involve GSR.
These could be manifest in intact cells.
The effect of 1,4-NQs on mitochondrial function [16] could play a major role in their activ-
ity and selectivity. Indeed, we found that most non-toxic compounds inhibited oxygen con-
sumption supported by Complex I in bovine heart mitochondria. It is noteworthy that
mitochondrial respiration was stimulated by the Complex I substrate NADH, which is also
used as a donor of electrons in NADH/NADPH dehydrogenase-mediated reduction of
1,4-NQs. Mitochondrial function was measured by the rate of NADH oxidation. Thus, actual
inhibition of mitochondrial function should be greater than that we measured because of these
two simultaneous reactions: Complex I and NADH/NADPH dehydrogenase. Indeed, the non-
toxic compounds that showed induction of mitochondrial function (compounds 1, 66, and
67) had the highest ability to generate ROS in NADH/NADPH dehydrogenase-mediated
reaction.
In contrast, all toxic compounds with one exception (compound 39 with 9% inhibition) did
not inhibit mitochondrial respiration. Again, toxic compounds 31, 32, 36, and 60 with the
highest ROS-inducing ability showed increased NADH oxidation in the Complex I activity
assay. Based on these data, we conclude that effects on mitochondrial respiration could con-
tribute to the selective anti-cancer activity of the non-toxic compounds. Indeed, we
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determined that the ability of the nontoxic compounds to inhibit oxygen consumption by
Complex I in bovine heart mitochondria is the only activity among tested that is significantly
different from that of the toxic compounds. On the other hand, the toxic compounds induced
cytotoxicity by mechanisms that are distinct from inhibition of mitochondrial respiration.
The mitochondria play a critical role in the production of ATP and the metabolites that are
necessary for biosynthesis of macromolecules such as nucleotides, fatty acids, and glutathione
[53]. The generation of ATP occurs via a set of mitochondrial intermembrane complexes I, III,
and IV that make up the ETC. Recent studies provided evidence that the mitochondrial ETC
might be a valuable target for cancer therapy [53, 54]. For example, it has been shown that met-
formin exerts anti-tumor effects partially through its ability to inhibit mitochondrial complex I
and exhibits an excellent safety profile [53, 55]. Another inhibitor of complex I activity, phen-
formin, also exerts its anti-tumor effects in orthotopic mouse models [56]. It is noteworthy
that, like NSC130362, inhibitors of mitochondrial function, including metformin and phenfor-
min, improve the anti-cancer effects of compounds that target PI3K and B-RAF signaling [57–
59]. Mitochondrial complex I inhibitors block tricarboxylic acid (TCA) cycle-mediated ATP
production and induce apoptosis by enhancing the generation of ROS. A ROS-based approach
to induce selective cytotoxicity in cancer cells has been recently validated by researchers at
Kolkata’s Indian Association for the Cultivation of Science (IACS) who have synthesized a
novel porphyrin compound with potent anti-cancer activity [60]. By targeting cellular topo-
isomerase 1 enzyme and producing increased ROS inside cells, this porphyrin compound
showed potent cytotoxicity against cervical, ovarian, and colon cancer cells with significantly
reduced or no toxicity toward human embryonic kidney cell lines and mouse embryonic
fibroblasts.
Although most cancer cells have functional mitochondrial metabolism, some cancer cells
have mutations in the ETC and macromolecule biosynthesis proteins of their mitochondria
[61, 62]. These cancer cells are dependent on glycolysis to produce energy (Warburg effect).
Thus, inhibiting glycolysis is an efficient way to target these ETC-mutated cancer cells. In addi-
tion, one of the key hallmarks of cancer is to re-program metabolic capability, which leads to
elevated glycolytic metabolism in cancer cell [63]. Thus, it has been hypothesized that inhibi-
tion of both mitochondrial metabolism and glycolysis could be an effective anti-cancer therapy
[64]. GAPDH catalyzes the conversion of glyceraldehyde 3-phosphate to D-glycerate
1,3-bisphosphate in the process of glycolysis [65]. Because GAPDH is one of the possible tar-
gets of 1,4-NQ, we evaluated the selected compounds in cell-based GAPDH inhibition assays.
None of the non-toxic compounds inhibited GAPDH by more than 27%. In contrast, two the
most toxic compounds (compounds 31 and 32) almost completely inhibited GAPDH. Because
the same compounds were the most efficient inhibitors of GSR, we speculated that this dual
effect can be responsible for the high level of toxicity to hepatocytes and, as a consequence, the
lowest selective cytotoxicity index of compounds 31 and 32. Other toxic compounds inhibited
GAPDH with narrow range of 0–12%. We conclude that targeting glycolysis is not the factor
that is responsible of the selective anti-cancer activity of the non-toxic compounds.
The results described above allow us to predict that targeting mitochondrial ETC could be
the key biological activity that can be used to guide non-toxic compound optimization. We
can also speculate that distinct effects of the non-toxic and toxic compounds on mitochondrial
function are governed by multiple structural factors that include but are not limited to elec-
tronic, hydrophobic, and steric characteristics of substituents and their position in the quinone
ring [66, 67]. To account for available physico-chemical factors that most likely affect com-
pound activities, we performed molecular modeling to develop a QSAR model. Molecular
modeling employed computational-based descriptors to correlate biological activity in cellular
systems. Based on the structure of the non-toxic and toxic compounds, Q-MOL developed a
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fitness function (AFPs) to describe accurately the relationship between the molecular structure
of a chemical and its anti-tumor potency and safety toward normal cells. Encouragingly, there
was a clear difference in the AFPs between the non-toxic and toxic compounds, which con-
firmed that the AFP-based QSAR model could be trained by docking ligands into AFP distri-
butions and then used as an energy-based classifier to differentiate between non-toxic and
toxic ligands. Thus, we concluded that obtained QSAR model can be used to design non-toxic
compounds with potent anti-tumor activity. Overall, the obtained results improve our knowl-
edge regarding mechanisms of the selective anti-cancer activity.
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